The company focuses on innovation and development in the field of pharmaceutical intermediates, achieving remarkable results in the R&D and industrialized production of synthetic processes for API intermediates represented by Semaglutide and Tirzepatide. Meanwhile, it actively invests in the R&D of synthetic processes for API penicillamine series intermediates related to oral IL-23 (Icotrokinra), with outstanding achievements in the industrialization process. In addition, the company undertakes end-to-end services for customers' customized products, including R&D, production and sales.
The company is well-equipped with sophisticated laboratories, modern analytical equipment, multi-functional kilogram-scale laboratories and pilot production workshops. Its customers are located worldwide, covering pharmaceutical companies, biotechnology enterprises, agrochemical companies and special chemical companies.
Through continuous independent R&D, the company has successfully developed more than 20 industrialized products, including amino acid derivatives, a series of heterocyclic boronic acid products and polypeptide pharmaceutical intermediates, injecting new vitality into the development of the pharmaceutical intermediate field.
Honors: Excellence Award in the Start-up Group of the 13th China Innovation and Entrepreneurship Competition; First Prize in the Start-up Group of the 10th Dalian Innovation and Entrepreneurship Competition.
